{
    "pmcid": "8451865",
    "qa_pairs": {
        "What biophysical characteristic of the sdAb is used to predict the necessary pH of the bridging buffer for purification?": [
            "Isoelectric point (pI) of the variable region",
            "Molecular weight",
            "Thermal stability",
            "Hydrophobicity index"
        ],
        "What is a key advantage of nanobodies over conventional antibodies mentioned in the paper?": [
            "Their small size allows them to bind to targets inaccessible to larger antibodies.",
            "They have a longer half-life in the bloodstream.",
            "They are less expensive to produce.",
            "They have a broader range of antigen recognition."
        ],
        "What organism is used in the novel platform for producing single-domain antibodies as described in the paper?": [
            "Komagataella phaffii (Pichia pastoris)",
            "Escherichia coli",
            "Saccharomyces cerevisiae",
            "Bacillus subtilis"
        ],
        "What purification method is used in the platform to avoid the use of affinity tags?": [
            "Multimodal cation exchange and salt-tolerant anion exchange chromatography",
            "Size-exclusion chromatography",
            "Protein A affinity chromatography",
            "Hydrophobic interaction chromatography"
        ],
        "What was demonstrated by the nonclinical studies of sdAbs produced using the platform?": [
            "Protection against viral shedding and disease symptoms in animal models",
            "Increased half-life in the bloodstream",
            "Enhanced binding affinity compared to traditional antibodies",
            "Reduced immunogenicity in human trials"
        ]
    }
}